List view / Grid view
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
A three-pronged antibody has been found to protect from infection with two strains of SHIV, better than individual natural antibodies...
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
Amorsa Therapeutics' CSO, Michael Palfreyman, discusses how the party drug Ketamine can be used to target NMDA receptors and treat depression...
13 April 2016 | By Victoria White, Digital Content Producer
Sanofi has opened a partnering office at Stevenage Bioscience Catalyst to engage and collaborate with the UK's network of bioscience companies and academia...
29 March 2016 | By Victoria White
Dr Yong-Jun Liu has been appointed as Sanofi’s new Head of Research, Global R&D, effective...
17 March 2016 | By Victoria White
IPROVE has launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years...
